Previous 10 | Next 10 |
--News Direct-- Cybin Inc CEO Doug Drysdale joined Steve Darling from Proactive to share news the US Patent and Trademark Office has granted another patent to a deuterated psilocybin analog within the company's CYB003 investigational drug program. This patent is expected to provide ex...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has begun preparations for good manufacturing practices (“GMP”) production o...
- CYB003 capsule formulation is designed to be stable, dose flexible, patient-friendly and commercially scalable - - Shipments of CYB003 capsules to clinical sites expected in Q1 2024 - - R ecently granted U.S. patent covers composition of matter claims and treatment methods i...
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the U.S. Patent and Trademark Office (“USPTO”...
- Newly granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 - - Company’s intellectual property portfolio now encompasses 2 granted U.S. patents, and over 50 pending patent applications across 6 ...
Cybin (NEO: CYBN) (NYSE American: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting unaudited financial results for its first quarter, the period ended June 30, ...
- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 - - U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023 - - P...
2023-08-14 01:03:21 ET Summary COMPASS Pathways continues to make solid progress in its ambition to gain regulatory approval for COMP360 psilocybin-assisted therapy for treatment-resistant depression. The group has refined its strategy for the eventual monetization of COMP360, and...
Cybin (NYSE American: CYBN) (NEO: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, has closed its previously announced overnight marketed public offering. In connection with the...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce tha...
News, Short Squeeze, Breakout and More Instantly...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options for mental-health disorders, is reporting “a swell” of insider purchases followi...
Miami, Florida--(Newsfile Corp. - July 8, 2024) - Fast-moving sectors need equally fast-moving companies, a box that Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) checks, supported by a June 26th update on progress made in fiscal 2024 ending on March 31st. In its presser , Cybin highlighted k...